Abstract: Provided herein, at least in part, are methods of treating a hematologic malignancy in a human subject in need thereof, comprising orally administering to the subject duvelisib or a pharmaceutically acceptable form thereof.

Abstract: The present invention relates to methods for treating abnormal cell growth (e.g., cancer) in a subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) comprising administering to the subject an effective amount of a MEK inhibitor (e.g., a dual RAF/MEK inhibitor) alone or in combination with an additional agent.

Abstract: A liquid crystal cell includes substrates defining a gap and electrodes having one of (i) an in-plane geometry generating an electric field parallel with the substrates and (ii) a top-down geometry generating an electric field across the gap between the two spaced apart substrates. A liquid crystal material disposed in the gap between the substrates comprises a chiral nematic material formed by a mixture of: 1-(4-cyanobiphenyl-4?-yl)-6-(4-cyanobiphenyl-4?-yloxy)hexane (CB6OCB) or ?,?-bis(4,4-cyanobiphenyl)nonane (CB9CB) dimeric liquid crystal material; at least one additional dimeric liquid crystal material; and a chiral dopant.

Abstract: A liquid crystal cell includes substrates defining a gap and electrodes having one of (i) an in-plane geometry generating an electric field parallel with the substrates and (ii) a top-down geometry generating an electric field across the gap between the two spaced apart substrates. A liquid crystal material disposed in the gap between the substrates comprises a chiral nematic material formed by a mixture of: 1-(4-cyanobiphenyl-4?-yl)-6-(4-cyanobiphenyl-4?-yloxy)hexane (CB6OCB) or ?,?-bis(4,4-cyanobiphenyl)nonane (CB9CB) dimeric liquid crystal material; at least one additional dimeric liquid crystal material; and a chiral dopant.

Abstract: Prediction methods including statistical and artificial intelligence methods to predict the prescribing behavior and characteristics and size of patient populations under the care of health care providers from limited data, based on processes developed on integrated medical and pharmaceutical claims data. Prescribers can be classified into groups and subgroups, and marketing recommendations can be made to organizations with interest in the drug prescriptions based on prescription data; sales force effectiveness and marketing message effectiveness products can also be developed.